Crovalimab is unique in that it has a longer biological half-life than other C5 inhibitors and can be administered by subcutaneous injection, although the efficacy of the novel complement inhibitor crovalimab in bone marrow failure-associated PNH is more unclear. The gene discussed is C5; the disease is Bone marrow hypocellularity.